Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

Background: Successful vaccination against SARS-CoV2 is highly effective in preventing serious COVID-19 illness and is particularly recommended for at risk populations including patients with multiple myeloma (MM). However, there is uncertainty to which extent modern intensified therapies targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenner, Matthew W, Hall, Andrew, Faustini, Sian E, Pitchford, Alexandra, de Tute, Ruth M., Roberts, Sadie, Ingleson, Emma, Bowles, Kristian M, Garg, Mamta, Lokare, Anand, Messiou, Christina, Jackson, Graham, Pratt, Guy, Cook, Gordon, Owen, Roger G, Brown, Sarah R, Drayson, Mark T, Kaiser, Martin F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701702/
http://dx.doi.org/10.1182/blood-2021-149268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701702/
http://dx.doi.org/10.1182/blood-2021-149268

Ejemplares similares